News
ESPR
1.910
-2.05%
-0.040
Weekly Report: what happened at ESPR last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at ESPR last week (0408-0412)?
Weekly Report · 04/15 12:00
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Applied Digital Corporation shares fell sharply in today’s pre-market trading after the company reported worse-than-expected third-quarter financial results. The Dow futures fell over 50 points on Friday. U.S. Stock futures were lower in today's trading session.
Benzinga · 04/12 12:04
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Fastenal shares dipped 6.7% to $69.73 on Thursday. The company reported worse-than-expected first-quarter financial results. Rallybio Corporation shares climbed 89.6% after company announced a collaboration with Johnson & Johnson. Rent the Runway, Inc. Shares jumped 74.5% after the company reported mixed fourth-quarter results.
Benzinga · 04/11 17:33
Understanding Serge Belanger’s Buy Rating for Esperion (ESPR): A Critical Analysis
TipRanks · 04/10 10:55
Weekly Report: what happened at ESPR last week (0401-0405)?
Weekly Report · 04/08 12:06
Esperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groups
Esperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groups. Esperion Therapeutics shares gained 7% premarket on Monday. The company touted clinical benefits of NEXLETOL (bempedoic acid) tablets in diverse populations.
Seeking Alpha · 04/08 10:16
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Esperion Therapeutics, Inc. Shares rose sharply during today’s pre-market trading. The company presented new data from CLEAR outcomes at ACC. 24 highlighting value of NEXLETOL tablets in diverse populations. Longeveron Inc. And Galmed Pharmaceuticals Ltd. Were among the stocks moving in pre- market trading.
Benzinga · 04/08 09:15
Reported Sunday, Esperion Presents New Data From CLEAR Outcomes At ACCR 2024 Highlighting Value Of NEXLETOL® Tablets In Diverse Populations
Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo. Study demonstrated clinical benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients.
Benzinga · 04/08 06:41
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday. The company reportedly issued a weak outlook at the J.P. Morgan Retail Roundup investor conference. ARCA biopharma, Inc. Shares climbed 108% in the mid-day session.
Benzinga · 04/03 17:56
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
Signet Jewelers shares surged 9.2% to $103.80 on Wednesday. Shares of the company rose sharply after the company raised its FY25 guidance. Destiny Tech100 Inc. Shares jumped 21.4% and Ocugen shares jumped 14.2%. The Dow Jones gained over 50 points in Wednesday's session.
Benzinga · 04/03 14:31
Weekly Report: what happened at ESPR last week (0325-0329)?
Weekly Report · 04/01 12:03
After Hours Most Active for Mar 27, 2024 : ESPR, TLT, QQQ, KDP, KO, BMY, AAPL, AMZN, VSTS, WMT, CVX, BAC
NASDAQ · 03/27 20:24
Esperion’s Market Expansion and Positive Sales Outlook Merit a Buy Rating
Esperion (ESPR) was revisited by a Wall Street analyst yesterday. Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $9.00 price target. The new labeling for Esperion’s combination pill is more favorable than anticipated.
TipRanks · 03/26 10:15
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Landos Biopharma, Inc. Shares jumped 171.2% to $21.70 on Monday. AbbVie and Landos signed a definitive agreement to acquire the company. Altamira Therapeutics Ltd. Shares climbed 70.1% after falling around 22% on Friday. GameStop Corp. Shares rose 8.4% after the company announced a separation.
Benzinga · 03/25 18:44
Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Dow Jones · 03/25 17:10
Buy Rating Affirmed for Esperion on Growth Potential Post-FDA Approval
TipRanks · 03/25 17:05
HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Benzinga · 03/25 17:01
Esperion stock jumps 18% in wake of FDA label expansions
Esperion stock jumps 18% in wake of FDA label expansions. The FDA has broadened the labeling for its cardiovascular drugs Nexletol and Nexlizet. The drugs are also indicated for cardiovascular risk reduction and expanded LDL cholesterol lowering in both primary and secondary patients.
Seeking Alpha · 03/25 15:50
Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol
Esperion shares were up 16% to $2.67 after the company said the FDA approved broad new label expansions. The stock is now up 66% in the past 12 months. Esperion said the approval was based on positive data. The company said its pending label expansions in Europe remain on track.
Dow Jones · 03/25 15:03
More
Webull provides a variety of real-time ESPR stock news. You can receive the latest news about Esperion Therape through multiple platforms. This information may help you make smarter investment decisions.
About ESPR
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.